- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary insulin-like growth factor 1 deficiency
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 533KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 88KB)
Mecasermin – March 2022
Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex®
Last updated
1 July 2022